Table 1.
Clinical features of cystic fibrosis patients included in the study
| Sex (male) |
50% (80)# |
| Age |
17.72 ± 15.75 years (0.6 – 24 years)* |
| BMI - thinness and accentuated thinness |
22.22% (40)# |
| One Class I. II or III identified mutation |
28.33% (51)# |
| Two Class I. II or III identified mutation |
47.22% (85)# |
| First clinical manifestation |
2.90 ± 8.89 years (0 – 13 years)* |
| Age at diagnosis |
7.62 ± 13.63 years (0 – 14.23 years)* |
| Onset of digestive symptoms |
3.39 ± 9.11 years (0 – 12.45 years)* |
| Onset of pulmonary symptoms |
2.90 ± 9.89 years (0 – 13 years)* |
| SpO2 |
94.92 ± 4.26 (66 – 99)* |
| Bhalla score |
8.74 ± 5.724 (0 – 25)* |
| Kanga score |
18.85 ± 5.84 (10 – 40)* |
| Shwachman-Kulczycki score |
65.85 ± 16.77 (20 – 95)* |
| FVC (%) |
79.29 ± 23.55 (19 – 135)* |
| FEV1 (%) |
71.29 ± 27.47 (17 – 132)* |
| FEV1/FVC (%) |
83.46 ± 15.95 (37 – 137)* |
| FEF25-75% |
59.05 ± 35.55 (7 – 150)* |
| Nasal Polyps |
18.33% (33)# |
| Diabetes mellitus |
18.33% (33)# |
| Osteoporosis |
16.11% (29)# |
| Pancreatic insufficiency |
80.0% (144)# |
| Meconium ileus |
15.00% (27)# |
| First isolated P. aeruginosa |
8.55 ± 14.45 years (2 – 15 years) |
|
P. aeruginosa status |
56.67% (102)# |
|
P. aeruginosa mucoid status |
42.22% (76)# |
|
B. cepacia status |
13.88% (25)# |
|
A. xylosoxidans status |
10.00% (18)# |
| S. aureus status | 78.88% (142)# |
BMI body mass index, SpO2 Hemoglobin oxygen saturation in the blood, % percentage, FVC forced vital capacity, FEV1 forced expiratory volume in the first second, FEF25-75 forced expiratory flow between 25 and 75% of FVC. 2. Based on 3 Consecutive positive respiratory cultures.
# Percentage (Number of patients).
* Continuous variables expressed as mean ± SD (range).